LEVETIRACETAM DEXCEL 250

País: Israel

Idioma: anglès

Font: Ministry of Health

ingredients actius:

LEVETIRACETAM

Disponible des:

DEXCEL PHARMA TECHNOLOGIES LTD

Codi ATC:

N03AX14

formulario farmacéutico:

TABLETS

Composición:

LEVETIRACETAM 250 MG

Vía de administración:

PER OS

tipo de receta:

Required

Fabricat per:

DEXCEL LTD, ISRAEL

Grupo terapéutico:

LEVETIRACETAM

Área terapéutica:

LEVETIRACETAM

indicaciones terapéuticas:

Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Dexcel is indicated as adjunctive therapy:• In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.• In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Data d'autorització:

2018-03-31